IASO Bio reports 90 percent response rate for CAR T therapy
Biotechnology developer IASO Bio announced a 90 percent objective response rate from first in human clinical trials evaluating its IASO206 in vivo CAR T candidate for multiple myeloma
IASO Bio, a commercial-stage biopharmaceutical company focused on innovative cell therapies and biologics, has reported an impressive 90 percent response rate for its internally developed BCMA-targeted in vivo CAR-T cell therapy, IASO206. This data was presented at the 2026 International Myeloma Society (IMS) Annual Meeting by Dr. Wenqiang Yan of the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences.
The FIH Phase 1 clinical trial enrolled patients with relapsed/refractory multiple myeloma (R/R MM) who had received at least two prior lines of therapy and had relapsed or refractory disease following treatment with proteasome inhibitors, immunomodulatory agents, and/or anti-CD38 antibodies. The trial evaluated three dose levels and demonstrated robust in vivo expansion of CAR-positive cells, as well as deep clinical responses, with 90% of patients achieving an objective response rate (ORR) and 90% having minimal residual disease (MRD) negativity.
The safety profile of IASO206 was found to be manageable, with no dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or treatment-related deaths reported.
Brief written by urgent.news from Vietnam Investment Review's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
